Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

609

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Essential Hypertension
Interventions
DRUG

Azilsartan medoxomil and chlorthalidone

"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."

DRUG

Azilsartan medoxomil and hydrochlorothiazide

"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."

Trial Locations (53)

Unknown

Birmingham

Gulf Shores

Scottsboro

Gilbert

Sierra Vista

Paramount

Sacramento

San Diego

Colorado Springs

Wheat Ridge

Milford

Adventura

Aventura

Brooksville

Crystal River

DeLand

Doral

Miami

Naranja

Sarasota

Tampa

West Palm Beach

Winter Haven

Atlanta

Stockbridge

Suwanee

Huntsville

Bloomington

Valparaiso

Crestview Hills

Lexington

West Yarmouth

Ann Arbor

City of Saint Peters

St Louis

New Windsor

Asheboro

Cincinnati

Kettering

Downingtown

Lancaster

Lansdale

Pittsburgh

Goose Creek

Taylors

Bryan

San Antonio

Ettrick

Seattle

Madison

Moscow

Perm

Saint Petersburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00818883 - Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension | Biotech Hunter | Biotech Hunter